VitaVitro Biotech
韦拓生物
VitaVitro Biotech (韦拓生物) is an assisted-reproductive-technology (ART) supplier that Dalton Venture has backed and repeatedly highlights as a portfolio example. Per Dalton's own reporting, it is the first and, at the time of writing, the only domestic company to have secured all seven required product certificates in its field, and it had already moved into commercialization . Dalton led the company's Series B round, which was aimed at scaling its international ART-supplier capabilities .
elsewhere's corpus does not contain additional independent coverage of VitaVitro's founding date, team, or detailed product pipeline beyond these Dalton Venture references.
AI-generated — may contain errors, please verify.
Coverage
From Early Innovation to Industry Recognition: A Map of Dalton Venture's Specialized and Innovative Portfolio Companies
"Specialized, refined, distinctive, and innovative" enterprises are increasingly becoming a key benchmark for assessing the growth quality of China's technology and innovation companies. It represents not only a company's technical strength, innovation capability, and growth potential in niche sectors, but also serves as external validation from the industrial system of the value of outstanding SMEs. Recently, **Xuanyu Medical**, a **Dalton Venture family company**, was once again named to **Shanghai's second batch of 2026 specialized, refined, distinctive, and innovative SMEs. This marks Xuanyu Medical's continued recognition following its 2023 selection.
Steady Steps Toward Renewal, Momentum Into Waves | DTX 2025 Annual Review
Those who walk deeper into the cycle always spot the next beam of light.
Steadfast Progress, Grounded in Action | Dalton Venture's 2024 Year in Review
Looking back at 2024, "adjustment" and "patience" became the defining keywords for venture capital. Yet on the long-distance track of life sciences and medtech, Dalton Venture kept moving forward with steady, deliberate strides. We navigated market fluctuations, caught glimpses of innovation, and helped companies take root and grow through the cycles — writing a new chapter of innovation-driven development with the power of capital.
Dalton Venture's Sun Qi: Prioritize Hard-Tech Sectors That Serve National Needs, Prioritize Solving Supply Chain Security Issues | Dalton Insights
At the "2023 China Investment Annual Conference" summit, Sun Qi shared his perspectives and experience with fellow guests on the topic of *How Much Longer Is the Window for Domestic Substitution in Medical Devices?*
The Essential GP Skillset Today: Reading Policy, Reading the Macro Trend, and Getting the Timing Right | Dalton Insight
China's past economic growth was bought with high-intensity input of production factors. The only way to break through going forward is to use technology to transform production relations and shift toward high-quality development.
